Hanmi Pharmaceuticals Co Ltd (128940) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Hanmi Pharmaceuticals Co Ltd (Hanmi Pharma), a subsidiary of Hanmi Science Co Ltd is a developer of prescription drugs and over the counter drugs. The companys prescription drugs include osteoporosis, antibiotics, antidiarrheal, liver supplements and antiemetics. It provides over the counter products such as vitamins, nutritional supplements and calcium supplement, among others. Hanmi Pharmas products are used in the treatment of cancer, depression, dementia, dermatology, diabetes, anti-inflammatory, cardiovascular, epilepsy, hepatitis, hypnotics, osteoarthritis, gastrointestinal, osteoporosis and others. The company operates through its manufacturing facilities located in Hwaseong, Songpa, and Pyeongtaek, South Korea. Hanmi Pharma is headquartered in Seoul, South Korea.

Hanmi Pharmaceuticals Co Ltd (128940) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

It derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Hanmi Pharmaceuticals Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Cell>Point And Hyun IMC Expand Licensing Agreement To Include Hanmi Pharma For Cancer And Heart Disease Imaging 13
Hanmi Pharma Enters into Co-Development Agreement with Innovent Biologics 15
Serenus Biotherapeutics Enters into Co-Marketing with Hanmi Pharma 16
Hanmi Pharma Enters into Co-Marketing Agreement with Novartis Korea 17
Hanmi Pharma Enters into Co-promotion Agreement with Merck Sharp & Dohme Korea 18
Kainos Medicine Enters into Co-Development Agreement with Hanmi Pharm 19
Hanmi Pharma Enters Into Co-Marketing Agreement With Sanofi-Aventis For Ibestin 20
Hanmi Pharma Enters Into Co-Development Agreement With GlaxoSmithKline For EBF Products 21
Licensing Agreements 22
Sanofi Enters into Licensing Agreement with Hanmi Pharma 22
Hanmi Pharma Enters into Licensing Agreement with Ajou University 23
Genentech to Enter into Licensing Agreement with Hanmi Pharma 24
Zai Lab Enters into Licensing Agreement with Hanmi Pharma 25
Janssen Pharma to Enter into Licensing Agreement with Hanmi Pharma 26
Eli Lilly to Enter into Licensing Agreement with Hanmi Pharma 27
Spectrum Pharma Enters into Licensing Agreement with Hanmi Pharma for Poziotinib 28
Allegro Ophthalmics Enters into Licensing Agreement with Hanmi Pharma for Luminate 29
Hanmi Pharm Enters into Licensing Agreement with Luye Pharma for Poziotinib 30
Spectrum Pharma Enters Into Licensing Agreement With Hanmi Pharma For SPI-2012 31
Access Pharma Enters Into Licensing Agreement With Hanmi Pharma For MuGard 32
Kinex Pharma Expands Licensing Agreement With Hanmi Pharma 33
Amneal Pharma Enters Into Licensing Agreement With Hanmi Pharma For Nexium Alternative 35
Hanmi Pharma Enters Into Licensing Agreement With AngioLab For Anti-Obesity Botanical Drug 36
Acquisition 37
Hanmi Pharma to Invest USD20 Million in Allegro Ophthalmics 37
Hanmi Pharmaceuticals Co Ltd - Key Competitors 38
Hanmi Pharmaceuticals Co Ltd - Key Employees 39
Hanmi Pharmaceuticals Co Ltd - Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Recent Developments 41
Product News 41
03/31/2017: Spectrum Pharmaceuticals Announces Presentation of Abstract on ROLONTIS (eflapegrastim) at the AACR 41
01/08/2018: Athenex Announces Chinese FDA Allowance of Investigational New Drug Application of Oraxol to Begin Clinical Trials 42
Product Approvals 43
Oct 29, 2018: Athenex announces FDA allowance of Investigational New Drug Application of Eribulin ORA to begin clinical trials 43
Apr 19, 2018: Athenex Receives U.S. FDA Orphan Drug Designation for Oraxol for the Treatment of Angiosarcoma 44
Jul 05, 2017: Athenex Announces Submission of Investigational New Drug Application of Oraxol to Chinese FDA 45
Clinical Trials 46
Sep 24, 2018: Spectrum Pharmaceuticals announces release of updated Poziotinib data from MD Anderson phase 2 study in Non-Small Cell Lung Cancer Patients 46
Sep 13, 2018: Spectrum expands Phase ll trial of poziotinib for NSCLC 47
Sep 05, 2018: Spectrum Pharmaceuticals announces release of Poziotinib abstract as part of the IASLC 19th World Conference on Lung Cancer 48
Jun 04, 2018: Athenex Announces Poster Presentations at ASCO Annual Meeting 50
Apr 23, 2018: Spectrum Pharmaceuticals Announces Publication of Poziotinib Data in Nature Medicine 51
Apr 17, 2018: Spectrum Pharmaceuticals Highlights Data Showing Poziotinib Overcomes De Novo Resistance of HER2 Exon 20 Insertion Mutations in NSCLC and Other Cancers at the American Association for Cancer Research (AACR) in Chicago 52
Apr 10, 2018: Spectrum Pharmaceuticals Announces Update of MD Andersons Phase 2 Data Studying Poziotinib in EGFR Exon 20 Mutant Non-Small Cell Lung Cancer Patients 53
Feb 15, 2018: Athenex Meets Enrollment Target for Oraxol Phase III Clinical Trial in Metastatic Breast Cancer 54
Jan 22, 2018: Athenex Announces Encouraging Early Clinical Efficacy and Safety Data of Oraxol in Clinical Trial for the Treatment of Breast Cancer 55
Jan 22, 2018: Athenex Announces Encouraging Results of the First Cohort of Phase I Clinical Trial of Oraxol and CYRAMZA (Ramucirumab) Combination Treatment in Gastric Cancer 56
Jan 16, 2018: Athenex Receives Positive Feedback from FDA on the Design of Phase III Clinical Trial for Oraxol 57
Dec 27, 2017: Athenex Receives Promising Innovative Medicine Designation from the United Kingdom MHRA for Oraxol, An Innovative Oral Form of Paclitaxel 58
Nov 20, 2017: ESMO Asia 2017: Athenexs Oraxol (Oral Paclitaxel, Athenex) Can Achieve Similar Exposure to IV Paclitaxel in Cancer Patients 59
Oct 30, 2017: Spectrum Pharmaceuticals Announces Initiation of a Multicenter Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer (NSCLC) Patients with Exon 20 Insertion Mutation in EGFR or HER2 60
Oct 17, 2017: Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Japan 61
Oct 05, 2017: Athenex Announces Positive Recommendations from the Drug Safety Monitoring Board to Continue the Oraxol Phase III Program 62
Sep 28, 2017: Spectrum Pharmaceuticals Highlights Poziotinib Data in Lung Cancer to be Presented in an Oral Presentation at the 18th IASLC World Conference on Lung Cancer in Yokohama, Japan, October 15-18, 2017 63
Aug 01, 2017: Spectrum Pharmaceuticals Announces Completion of Enrollment in the Phase 3 Pivotal Study (ADVANCE) of ROLONTIS (eflapegrastim), a Novel Long-Acting GCSF 65
Jul 19, 2017: Athenex, Announces Commencement of Patient Enrollment for Oraxol-plus-Ramucirumab Phase 1b Clinical Trial in Gastric Cancer 66
May 05, 2017: Hanmi Pharmaceutical Announced IND Approval of HM95573, a Novel Oral RAF inhibitor 67
Apr 04, 2017: Spectrum Pharmaceuticals Highlights Preclinical Data of ROLONTIS (eflapegrastim) at the American Association for Cancer Research (AACR) Annual Meeting 68
Mar 30, 2017: Spectrum Pharmaceuticals Announces Initiation of a Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations 69
Mar 28, 2017: Athenex Announces the US FDA Allowance of the Investigational New Drug Application of Oratopo, A Combination of HM30181A and Oral Topotecan For the Treatment of Advanced Cancer 70
Jan 06, 2017: Hanmi presents pan-RAF inhibitor preclinical trial results at Europe Cancer Symposium 71
Appendix 72
Methodology 72
About GlobalData 72
Contact Us 72
Disclaimer 72

List Of Tables


Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Hanmi Pharmaceuticals Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Hanmi Pharmaceuticals Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Cell>Point And Hyun IMC Expand Licensing Agreement To Include Hanmi Pharma For Cancer And Heart Disease Imaging 13
Hanmi Pharma Enters into Co-Development Agreement with Innovent Biologics 15
Serenus Biotherapeutics Enters into Co-Marketing with Hanmi Pharma 16
Hanmi Pharma Enters into Co-Marketing Agreement with Novartis Korea 17
Hanmi Pharma Enters into Co-promotion Agreement with Merck Sharp & Dohme Korea 18
Kainos Medicine Enters into Co-Development Agreement with Hanmi Pharm 19
Hanmi Pharma Enters Into Co-Marketing Agreement With Sanofi-Aventis For Ibestin 20
Hanmi Pharma Enters Into Co-Development Agreement With GlaxoSmithKline For EBF Products 21
Sanofi Enters into Licensing Agreement with Hanmi Pharma 22
Hanmi Pharma Enters into Licensing Agreement with Ajou University 23
Genentech to Enter into Licensing Agreement with Hanmi Pharma 24
Zai Lab Enters into Licensing Agreement with Hanmi Pharma 25
Janssen Pharma to Enter into Licensing Agreement with Hanmi Pharma 26
Eli Lilly to Enter into Licensing Agreement with Hanmi Pharma 27
Spectrum Pharma Enters into Licensing Agreement with Hanmi Pharma for Poziotinib 28
Allegro Ophthalmics Enters into Licensing Agreement with Hanmi Pharma for Luminate 29
Hanmi Pharm Enters into Licensing Agreement with Luye Pharma for Poziotinib 30
Spectrum Pharma Enters Into Licensing Agreement With Hanmi Pharma For SPI-2012 31
Access Pharma Enters Into Licensing Agreement With Hanmi Pharma For MuGard 32
Kinex Pharma Expands Licensing Agreement With Hanmi Pharma 33
Amneal Pharma Enters Into Licensing Agreement With Hanmi Pharma For Nexium Alternative 35
Hanmi Pharma Enters Into Licensing Agreement With AngioLab For Anti-Obesity Botanical Drug 36
Hanmi Pharma to Invest USD20 Million in Allegro Ophthalmics 37
Hanmi Pharmaceuticals Co Ltd, Key Competitors 38
Hanmi Pharmaceuticals Co Ltd, Key Employees 39
Hanmi Pharmaceuticals Co Ltd, Other Locations 40
Hanmi Pharmaceuticals Co Ltd, Subsidiaries 40

List Of Figures


Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Hanmi Pharmaceuticals Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10

Hanmi Pharmaceuticals Co Ltd (128940) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Hanmi Pharmaceuticals Co Ltd (Hanmi Pharma), a subsidiary of Hanmi Science Co Ltd is a developer of prescription drugs and over the counter drugs. The companys prescription drugs include osteoporosis,

USD 250 View Report

Hanmi Pharmaceuticals Co Ltd (128940) - Financial and Strategic SWOT Analysis Review

Hanmi Pharmaceuticals Co Ltd (128940) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled

USD 125 View Report

North America Pharmaceuticals Cold Chain Logistics Market Report (2014-2024) - Market Size, Share, Price, Trend and Forecast

Abstract:The North America Pharmaceuticals Cold Chain Logistics market size is $XX million USD in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million

USD 3000 View Report

Global Pharmaceuticals Cold Chain Logistics Market Report 2019 - Market Size, Share, Price, Trend and Forecast

The global market size of Pharmaceuticals Cold Chain Logistics is $XX million in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million by

USD 4000 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available